血液學領域的合作研究和許可協議（2016-2026）

本報告分析了血液學領域的 226 項合作研究和許可協議，清楚地、以證據為基礎地展示了整個市場夥伴關係的設計、協商和執行方式。

目錄

摘要整理

第1章：引言

第2章：血液學合約的發展趨勢

• 介紹
• 過去幾年血液學領域的合作
• 血液學合作：依合約類型分類
• 血液學合作：按產業分類
• 血液學合作：依發展階段
• 血液學合作：依技術類型分類
• 血液學協作：依治療指徵

第3章 血液學合作的財務合約條款

• 介紹
• 血液學合作計畫的公開財務條款和條件
• 血液學合作的主要金額
• 血液學合約預付款
• 血液學合約的里程碑付款
• 血液學權利金費率

第4章：血液學領域的主要合約和承包公司

• 介紹
• 在血液學合作領域最積極主動的公司
• 血液學領域最活躍的合約公司名單
• 按金額排名的頂級血液學合約

第5章：血液學合約記錄

• 介紹
• 可提供合約的血液學合作協議

第6章 血液學合約：依治療標靶分類

• 介紹
• 合約：透過血液學治療標靶
• 合約記錄
• 合約記錄 - 血液學合約：按公司分類 (AZ)
• 合約記錄 - 血液學合約：按技術類型分類
• 合約類型的定義
• 關於 Biopharma Research Ltd.
• Current Partnering
• Current Agreements
• 理想合作夥伴近期報告標題

The definitive benchmark for hematology dealmaking

Hematology partnering spans both malignant and non-malignant disorders, with deal structures reflecting the increasing use of targeted therapies, biologics, and advanced treatment modalities across the space.

This report provides a comprehensive and structured analysis of 226 hematology collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how hematology deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a technically advanced and evolving therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within hematology partnerships, particularly in areas involving complex development pathways and high-value therapies.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 226 hematology collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for hematology dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how hematology partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in hematology dealmaking

• 2.1. Introduction
• 2.2. Hematology partnering over the years
• 2.3. Hematology partnering by deal type
• 2.4. Hematology partnering by industry sector
• 2.5. Hematology partnering by stage of development
• 2.6. Hematology partnering by technology type
• 2.7. Hematology partnering by therapeutic indication

Chapter 3 - Financial deal terms for hematology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for hematology partnering
• 3.3. Hematology partnering headline values
• 3.4. Hematology deal upfront payments
• 3.5. Hematology deal milestone payments
• 3.6. Hematology royalty rates

Chapter 4 - Leading hematology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in hematology partnering
• 4.3. List of most active dealmakers in hematology
• 4.4. Top hematology deals by value

Chapter 5 - Hematology contract document directory

• 5.1. Introduction
• 5.2. Hematology partnering deals where contract document available

Chapter 6 - Hematology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by hematology therapeutic target
• Deal directory
• Deal directory - Hematology deals by company A-Z
• Deal directory - Hematology deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Hematology partnering since 2016
• Figure 2: Hematology partnering by deal type since 2016
• Figure 3: Hematology partnering by industry sector since 2016
• Figure 4: Hematology partnering by stage of development since 2016
• Figure 5: Hematology partnering by technology type since 2016
• Figure 6: Hematology partnering by indication since 2016
• Figure 7: Hematology deals with a headline value
• Figure 8: Hematology deals with upfront payment values
• Figure 9: Hematology deals with milestone payment
• Figure 10: Hematology deals with royalty rates
• Figure 11: Active hematology dealmaking activity since 2016
• Figure 12: Top hematology deals by value since 2016